Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ADN012
MIFTS: 42

Adenocarcinoma in Situ

Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Adenocarcinoma in Situ

About this section

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ 12 43 15 71

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4943
MeSH 43 D065311
NCIt 49 C4123
SNOMED-CT 67 51642000
UMLS 71 C0334276
Sources

Summaries for Adenocarcinoma in Situ

About this section
Disease Ontology : 12 An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Adenocarcinoma in Situ is related to early invasive cervical adenocarcinoma and adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Bladder cancer. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and testes, and related phenotypes are Reduced mammosphere formation and cellular

Sources

Related Diseases for Adenocarcinoma in Situ

About this section

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 363)
# Related Disease Score Top Affiliating Genes
1 early invasive cervical adenocarcinoma 32.4 INSM1 CDKN2A
2 adenocarcinoma 30.7 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
3 neuroendocrine carcinoma 30.6 KRT7 KRT20 CEACAM5
4 adenoma 30.6 KRT7 KRAS CDX2 CDKN2A
5 cervical adenocarcinoma 30.6 KRT7 KRT20 EGFR CEACAM5 CDX2 CDKN2A
6 papillary adenocarcinoma 30.5 MIR21 KRT7 KRAS CEACAM5
7 urachal adenocarcinoma 30.4 KRAS CEACAM5
8 appendix adenocarcinoma 30.4 KRT7 KRT20 KRAS CEACAM5 CDX2
9 cystadenoma 30.3 KRT7 KRT20 CEACAM5
10 eccrine papillary adenoma 30.3 KRAS CEACAM5
11 duodenum adenocarcinoma 30.3 KRT7 KRAS CDX2
12 mature teratoma 30.2 KRT7 KRAS CEACAM5
13 glandular cystitis 30.2 KRT7 KRT20 CDX2
14 villous adenoma 30.1 KRT20 KRAS CEACAM5 CDX2
15 benign teratoma 30.0 KRT7 KRT20 CEACAM5 CDX2
16 mammary paget's disease 29.9 KRT7 KRT20 EGFR
17 endocervical adenocarcinoma 29.9 U2AF1 PAX8 PAX2 KRT7 KRT20 CEACAM5
18 pseudomyxoma peritonei 29.8 KRT7 KRT20 KRAS CEACAM5 CDX2
19 cervical squamous cell carcinoma 29.8 KRAS EGFR CDKN2A
20 endometrial adenocarcinoma 29.8 KRT7 KRAS EGFR CDKN2A
21 adenosquamous carcinoma 29.8 KRT7 KRAS EGFR CEACAM5
22 bronchiolo-alveolar adenocarcinoma 29.8 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
23 large cell neuroendocrine carcinoma 29.7 KRT7 KRT20 EGFR
24 cystic teratoma 29.6 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
25 teratoma 29.6 KRT7 KRT20 KRAS CEACAM5 CDX2 CDKN2A
26 transitional cell carcinoma 29.5 KRT7 KRT20 EGFR CDKN2A
27 mucinous adenocarcinoma 29.4 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
28 papilloma 29.4 KRT7 KRT20 KRAS EGFR CDKN2A
29 barrett esophagus 29.3 MCM2 KRT7 KRT20 EGFR CDX2 CDKN2A
30 intrahepatic cholangiocarcinoma 29.3 KRT7 KRT20 KRAS EGFR CDX2
31 colorectal adenocarcinoma 29.1 KRT7 KRT20 KRAS EGFR CEACAM5 CDX2
32 ovarian mucinous neoplasm 29.1 U2AF1 PAX8 KRT7 KRT20 KRAS CEACAM5
33 colon adenocarcinoma 29.1 MIR21 KRT20 KRAS EGFR CEACAM5
34 peritoneum cancer 29.0 WT1 PAX8 KRT7 EGFR CEACAM5 CDKN2A
35 endometrial cancer 29.0 WT1 PAX8 KRT7 KRT20 KRAS EGFR
36 lung cancer susceptibility 3 28.6 U2AF1 TOP2A MIR21 KRT7 KRT20 KRAS
37 cholangiocarcinoma 27.8 MIR21 KRT7 KRT20 KRAS EGFR CEACAM5
38 in situ pulmonary adenocarcinoma 11.4
39 cervical basaloid squamous cell carcinoma 10.6 KRT7 CDKN2A
40 trachea carcinoma in situ 10.6 KRAS CDKN2A
41 parotid gland adenoid cystic carcinoma 10.6 CEACAM5 CDKN2A
42 inverted transitional papilloma 10.6 KRT7 CDKN2A
43 signet ring basal cell carcinoma 10.6 KRAS CEACAM5
44 endometrial transitional cell carcinoma 10.6 KRT7 CDKN2A
45 bladder signet ring cell adenocarcinoma 10.6 KRT7 CDX2
46 ovary neuroendocrine neoplasm 10.6 KRT7 CDX2
47 malignant spiradenoma 10.6 KRT7 CEACAM5
48 vagina leiomyoma 10.6 CEACAM5 CDKN2A
49 anus basaloid carcinoma 10.6 KRT7 CDKN2A
50 cutaneous mucoepidermoid carcinoma 10.6 KRT7 CEACAM5

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:



Diseases related to Adenocarcinoma in Situ
Sources

Symptoms & Phenotypes for Adenocarcinoma in Situ

About this section

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CLDN1 EGFR KRAS KRT7 MCM2 MCM7

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.1 CDKN2A CDX2 EGFR GGN INSM1 KRAS
2 mortality/aging MP:0010768 10 ASPH CDKN2A CDX2 CLDN1 EGFR GGN
3 endocrine/exocrine gland MP:0005379 9.91 CDKN2A CDX2 EGFR INSM1 KRAS MCM2
4 neoplasm MP:0002006 9.5 ASPH CDKN2A CDX2 EGFR KRAS MCM2
5 pigmentation MP:0001186 9.02 CDKN2A EGFR KRAS MCM2 PAX2
Sources

Drugs & Therapeutics for Adenocarcinoma in Situ

About this section

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4
2 Immunologic Factors Phase 4
3
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
4
Methamphetamine Approved, Illicit Phase 3 537-46-2 10836
5 Sympathomimetics Phase 3
6 Dopamine Uptake Inhibitors Phase 3
7 Dopamine Agents Phase 3
8 Neurotransmitter Agents Phase 3
9 Central Nervous System Stimulants Phase 3
10 Autonomic Agents Phase 3
11 Adrenergic Agents Phase 3
12
Metformin Approved Phase 2 657-24-9 14219 4091
13
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
14
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
15
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 58-22-0, 481-30-1 6013 10204
16
nivolumab Approved Phase 2 946414-94-4
17
Ipilimumab Approved Phase 2 477202-00-9
18 Hypoglycemic Agents Phase 2
19 Alkylating Agents Phase 1, Phase 2
20 Hormone Antagonists Phase 1, Phase 2
21 Antirheumatic Agents Phase 1, Phase 2
22 Hormones Phase 1, Phase 2
23 Androgens Phase 1, Phase 2
24 Immunosuppressive Agents Phase 1, Phase 2
25 Antineoplastic Agents, Immunological Phase 2
26 Antibodies, Monoclonal Phase 2
27 Antibodies Phase 2
28 Immunoglobulins Phase 2
29
acetic acid Approved 64-19-7 176
30
Proflavine Approved 92-62-6 7099
31
Fenbendazole Vet_approved 43210-67-9 3334
32
Retinol acetate 127-47-9 10245972
33 Lugol's solution
34 Pharmaceutical Solutions
35 Anti-Infective Agents, Local
36 Anti-Infective Agents

Interventional clinical trials:

(show all 30)
# Name Status NCT ID Phase Drugs
1 A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women Completed NCT01544478 Phase 4
2 A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study Recruiting NCT03180034 Phase 4
3 A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity Unknown status NCT01429649 Phase 3
4 A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam Completed NCT03546842 Phase 3
5 A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women Completed NCT00092521 Phase 3
6 A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women Completed NCT00834106 Phase 3
7 A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica. Completed NCT00128661 Phase 3
8 A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age Recruiting NCT03998254 Phase 3 V503;Gardasil
9 A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years Active, not recruiting NCT03493542 Phase 3
10 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
11 Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study Completed NCT03053544 Phase 2 Metformin
12 A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy Completed NCT01696877 Phase 1, Phase 2 degarelix acetate;Cyclophosphamide;GVAX
13 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
14 Conservative Surgery for Women With Low-risk, Early Stage Cervical Cancer Active, not recruiting NCT01048853 Phase 2
15 Establishment and Evaluation for Pathological Diagnostic Criteria of Intraoperative Frozen Section of Early Stage Lung Cancer Unknown status NCT02941003
16 Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS) Unknown status NCT00898144
17 Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung Unknown status NCT02239432
18 Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil) Unknown status NCT03195218
19 Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings Completed NCT02494310
20 Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study Completed NCT03466710
21 Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC) Recruiting NCT00892866
22 A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity Recruiting NCT03322826
23 HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination? Recruiting NCT02937155
24 Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer Recruiting NCT02140021
25 Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix Active, not recruiting NCT02206048 Proflavine
26 A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing Active, not recruiting NCT01946100
27 A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice. Active, not recruiting NCT03438006
28 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Enrolling by invitation NCT02705404
29 A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland Enrolling by invitation NCT01393470
30 Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia Suspended NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Sources

Genetic Tests for Adenocarcinoma in Situ

About this section
Sources

Anatomical Context for Adenocarcinoma in Situ

About this section

MalaCards organs/tissues related to Adenocarcinoma in Situ:

40
Lung, Cervix, Testes, Colon, Thyroid, Breast, Ovary
Sources

Publications for Adenocarcinoma in Situ

About this section

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 1263)
# Title Authors PMID Year
1
Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. 61
30861114 2020
2
Feature-shared adaptive-boost deep learning for invasiveness classification of pulmonary sub-solid nodules in CT images. 61
32020649 2020
3
Will HPV vaccination prevent cervical cancer? 61
31962050 2020
4
Role of PET/CT in Management of Early Lung Adenocarcinoma. 61
31714848 2020
5
Identification of novel CD74-NRG2α fusion from comprehensive profiling of lung adenocarcinoma in Japanese never or light smokers. 61
32036070 2020
6
SOX17 expression and its down-regulation by promoter methylation in cervical adenocarcinoma in situ and adenocarcinoma. 61
31444787 2020
7
Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. 61
30980692 2020
8
Specimen Fragmentation and Loop Electrosurgical Excision Procedure and Cold Knife Cone Biopsy Outcomes. 61
31860572 2020
9
Morule-like features in pulmonary adenocarcinoma associated with epidermal growth factor receptor mutations: two case reports with targeted next-generation sequencing analysis. 61
31674165 2020
10
ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target. 61
31925985 2020
11
CT features and quantitative analysis of subsolid nodule lung adenocarcinoma for pathological classification prediction. 61
31992239 2020
12
Marginal radiomics features as imaging biomarkers for pathological invasion in lung adenocarcinoma. 61
31965255 2020
13
Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients. 61
31692283 2020
14
Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type. 61
31932920 2020
15
[Clinicopathological features of stratified mucin-producing neoplastic lesions of the cervix]. 61
31914531 2020
16
Intracapsular High-Grade Ductal Carcinoma In-Situ Ex Pleomorphic Adenoma of the Lacrimal Gland. 61
31743286 2020
17
Reduction in HPV16/18 prevalence among young women with high-grade cervical lesions following the Japanese HPV vaccination program. 61
31596999 2019
18
Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. 61
31319173 2019
19
Atypical glandular lesions of the cervix and risk of cervical cancer. 61
31853943 2019
20
Should Pathologically Noninvasive Lung Adenocarcinoma Larger Than 3 cm Be Classified as T1a? 61
31400323 2019
21
Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. 61
31755549 2019
22
New T1 classification. 61
31679135 2019
23
Effectiveness of 1, 2, AND 3 Human Papillomavirus Vaccine doses against HPV-16/18 positive High-grade Cervical Lesions. 61
31680146 2019
24
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. 61
31446140 2019
25
Genomic Underpinnings of Tumor Behavior in in situ and Early Lung Adenocarcinoma. 61
31747302 2019
26
Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. 61
31107973 2019
27
Genomic and immune profiling of pre-invasive lung adenocarcinoma. 61
31784532 2019
28
Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. 61
30734284 2019
29
Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age. 61
31604665 2019
30
Incidentally Detected Malignancies in Lung Transplant Explants. 61
31773056 2019
31
Risk of vaginal cancer among hysterectomised women with cervical intraepithelial neoplasia: a population-based national cohort study. 61
31769577 2019
32
Qualitative and quantitative imaging features of pulmonary subsolid nodules: differentiating invasive adenocarcinoma from minimally invasive adenocarcinoma and preinvasive lesions. 61
31903274 2019
33
Management and long-term outcomes of women with adenocarcinoma in situ of the cervix: A retrospective study. 61
31578727 2019
34
Analysis of CT morphologic features and attenuation for differentiating among transient lesions, atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive and invasive adenocarcinoma presenting as pure ground-glass nodules. 61
31601919 2019
35
A comparison between 2- and 3-dimensional approaches to solid component measurement as radiological criteria for sublobar resection in lung adenocarcinoma ≤ 2 cm in size. 61
30968225 2019
36
Can we predict histological outcome of distinctive cohorts of patients with glandular cell abnormalities on ThinPrep Papanicolaou testing based on human papillomavirus status, age, and associated squamous abnormalities? 61
31359607 2019
37
Adenocarcinoma in situ of the uterine cervix: Clinical practice guidelines from the Italian society of colposcopy and cervical pathology (SICPCV). 61
31352128 2019
38
Identification of gene and microRNA changes in response to smoking in human airway epithelium by bioinformatics analyses. 61
31568004 2019
39
Role of ThinPrep liquid-based cytology in evaluation of the endocervical canal in patients with abnormal cervical screening. 61
31186178 2019
40
An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. 61
30629194 2019
41
Adenocarcinoma in situ in type I congenital pulmonary airway malformation. 61
31226882 2019
42
Elevated expression of G protein-coupled receptor 30 (GPR30) is associated with poor prognosis in patients with uterine cervical adenocarcinoma. 61
31483053 2019
43
Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay. 61
31002831 2019
44
Pathologic discrepancies between colposcopy-directed biopsy and loop electrosurgical excision procedure of the uterine cervix in women with cytologic high-grade squamous intraepithelial lesions. 61
31912671 2019
45
Can texture features improve the differentiation of infiltrative lung adenocarcinoma appearing as ground glass nodules in contrast-enhanced CT? 61
31307637 2019
46
[Analysis of recurrence and its influencing factors in patients with cervical HSIL within 24 months after LEEP]. 61
31461810 2019
47
Endocervical adenocarcinoma in situ (AIS) with ovarian and pulmonary involvement: report of a case and review of the literature suggesting a "seed and soil hypothesis". 61
31309301 2019
48
Computed Tomography-Guided Transfissural Coil Localization of Lung Nodules. 61
31450246 2019
49
[Thoracoscopic Left Upper Division Segmentectomy for Multiple Ground-glass Nodules Using Preoperative Virtual-assisted Lung Mapping]. 61
31296803 2019
50
Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. 61
30879979 2019
Sources

Variations for Adenocarcinoma in Situ

About this section
Sources

Expression for Adenocarcinoma in Situ

About this section
Search GEO for disease gene expression data for Adenocarcinoma in Situ.
Sources

Pathways for Adenocarcinoma in Situ

About this section

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Primary Focal Segmental Glomerulosclerosis FSGS 1
11 WT1 PAX2 CLDN1
2
Bladder cancer 36 1
10.66 KRAS EGFR CDKN2A
Sources

GO Terms for Adenocarcinoma in Situ

About this section

Cellular components related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleolus GO:0005730 9.43 WT1 TOP2A PAX2 MCM7 MCM2 CDKN2A
2 MCM complex GO:0042555 8.62 MCM7 MCM2

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 10.04 WT1 PAX2 MIR21 EGFR CEACAM5
2 positive regulation of transcription, DNA-templated GO:0045893 10.01 WT1 PAX8 PAX2 EGFR CDX2 CDKN2A
3 negative regulation of cell proliferation GO:0008285 10 WT1 MIR21 INSM1 CDKN2A ASPH
4 positive regulation of cell migration GO:0030335 9.93 MIR21 INSM1 EGFR CLDN1
5 positive regulation of cell proliferation GO:0008284 9.91 PAX2 MIR21 KRAS INSM1 EGFR CDX2
6 regulation of protein stability GO:0031647 9.79 KRAS CDKN2A ASPH
7 cellular response to epidermal growth factor stimulus GO:0071364 9.7 PAX2 MCM7 EGFR
8 branching involved in ureteric bud morphogenesis GO:0001658 9.69 WT1 PAX8 PAX2
9 mesonephros development GO:0001823 9.63 PAX8 PAX2
10 double-strand break repair via break-induced replication GO:0000727 9.62 MCM7 MCM2
11 mesenchymal to epithelial transition GO:0060231 9.61 WT1 PAX2
12 metanephric mesenchyme development GO:0072075 9.6 WT1 PAX2
13 cellular response to gonadotropin stimulus GO:0071371 9.59 WT1 PAX8
14 pre-replicative complex assembly involved in nuclear cell cycle DNA replication GO:0006267 9.58 MCM7 MCM2
15 mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0003337 9.58 PAX8 PAX2
16 regulation of metanephric nephron tubule epithelial cell differentiation GO:0072307 9.57 PAX8 PAX2
17 pronephros development GO:0048793 9.56 PAX8 PAX2
18 metanephric S-shaped body morphogenesis GO:0072284 9.55 WT1 PAX8
19 metanephric nephron tubule formation GO:0072289 9.49 PAX8 PAX2
20 metanephric distal convoluted tubule development GO:0072221 9.48 PAX8 PAX2
21 positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis GO:0072108 9.46 PAX8 PAX2
22 negative regulation of mesenchymal cell apoptotic process involved in metanephros development GO:1900212 9.4 PAX8 PAX2
23 positive regulation of metanephric DCT cell differentiation GO:2000594 9.37 PAX8 PAX2
24 negative regulation of apoptotic process involved in metanephric nephron tubule development GO:1900218 9.32 PAX8 PAX2
25 negative regulation of apoptotic process involved in metanephric collecting duct development GO:1900215 9.26 PAX8 PAX2
26 negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis GO:0072305 9.16 PAX8 PAX2
27 pronephric field specification GO:0039003 8.96 PAX8 PAX2
28 metanephric epithelium development GO:0072207 8.8 WT1 PAX8 PAX2

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.28 WT1 TOP2A PAX8 PAX2 MCM7 MCM2
Sources

Sources for Adenocarcinoma in Situ

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....